Parker Institute for Cancer Immunotherapy

InstitutionResearch output, impact & collaborations

Parker Institute for Cancer Immunotherapy is a research organisation in San Francisco, US. OpenAlex records 2,373 works and 562,976 citations for it. 595 researchers list it as their most recent affiliation.

2,373

Works

562,976

Citations

595

Researchers

82.6

Avg h-index

IDs:ROR OpenAlex

How has Parker Institute for Cancer Immunotherapy's publication output changed over time?

ScholarIQpublication output · 2011–2021

Output grew0% over the shown period — from 1 works in 2011 to 1 in 2021.

2011201220142015201720182021

What are the most-cited papers on Parker Institute for Cancer Immunotherapy?

ScholarIQmost cited works

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer, Scott Gettinger, David C. Smith, David F. McDermott, John D. Powderly, Richard D. Carvajal, Jeffrey A. Sosman, Michael B. Atkins, Philip D. Leming, David R. Spigel, Scott Antonia, Leora Horn, Charles G. Drake, Drew M. Pardoll, Lieping Chen, William H. Sharfman, Robert A. Anders, Janis M. Taube, Tracee L. McMiller, Haiying Xu, Alan J. Korman, Maria Jure–Kunkel, Shruti Agrawal, D. G. McDonald, Georgia Kollia, Ashok Gupta, Jon M. Wigginton, Mario Sznol

New England Journal of Medicine. 201212,730 CitationsOPEN ACCESS

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

H. Borghaei, L. Paz-Ares, Leora Horn, David R. Spigel, Martin Steins, Neal Ready, Laura Q.M. Chow, Everett E. Vokes, Enriqueta Felip, Esther Holgado, Fabrice Barlési, Martin Kohlhäufl, Óscar Arrieta, M. Burgio, Jérôme Fayette, H. Lena, Elena Poddubskaya, David E. Gerber, Scott Gettinger, Charles M. Rudin, Naiyer A. Rizvi, Lucio Crinò, George R. Blumenschein, Scott Antonia, Cécile Dorange, Christopher Harbison, F. Graf Finckenstein, Julie R. Brahmer

New England Journal of Medicine. 20159,504 CitationsOPEN ACCESS

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

Julie R. Brahmer, Karen L. Reckamp, Paul Baas, Lucio Crinò, Wilfried Eberhardt, Elena Poddubskaya, Scott Antonia, Adam Płużański, Everett E. Vokes, Esther Holgado, David Waterhouse, Neal Ready, Justin F. Gainor, Osvaldo Arén Frontera, Libor Havel, Martin Steins, Marina Chiara Garassino, Joachim G.J.V. Aerts, Manuel Dómine, Luis Paz‐Ares, Martin Reck, Christine Baudelet, Christopher Harbison, Brian Lestini, David R. Spigel

New England Journal of Medicine. 20158,599 CitationsOPEN ACCESS

Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

Scott Antonia, Augusto Villegas, Davey B. Daniel, David Vicente, Shuji Murakami, Rina Hui, Takashi Yokoi, Alberto Chiappori, Ki Hyeong Lee, Maike de Wit, Byoung Chul Cho, Maryam Bourhaba, Xavier Quantin, Takaaki Tokito, Tarek Mekhail, David Planchard, Young‐Chul Kim, Christos S. Karapetis, Sandrine Hiret, Gyula Ostoros, Kaoru Kubota, Jhanelle E. Gray, Luis Paz‐Ares, Javier de Castro, Catherine Wadsworth, Giovanni Melillo, Haiyi Jiang, Yifan Huang, Phillip A. Dennis, Mustafa Özgüroğlu

New England Journal of Medicine. 20174,592 CitationsOPEN ACCESS

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

Daniel W Lee, James N. Kochenderfer, Maryalice Stetler‐Stevenson, Yongzhi Cui, Cindy Delbrook, Steven A. Feldman, Terry J. Fry, Rimas J. Orentas, Marianna Sabatino, Nirali N. Shah, Seth M. Steinberg, D. Stroncek, Nick Tschernia, Constance M. Yuan, Hua Zhang, Ling Zhang, Steven A. Rosenberg, Alan S. Wayne, Crystal L. Mackall

The Lancet. 20142,953 Citations